Chinese biopharmaceutical company Akeso Inc (HK:9926) announced on Wednesday that it has agreed a clinical trial collaboration and supply agreement with INOVIO (NASDAQ:INO), a US-based biotechnology company focused on developing and commercialising DNA medicines.

This agreement covers the evaluation of cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with INO-5412, INOVIO's DNA immunotherapy candidate, for the potential treatment of glioblastoma (GBM).

The combination therapy will be studied as a part of INSIGhT, the innovative Phase II adaptive platform trial sponsored by the Dana-Farber Cancer Institute and conducted with Mass General Brigham Cancer Care Inc, which is designed to quickly and efficiently find new treatments for GBM. Dosing in the combination therapy trial is expected to begin in the second half of 2026.